Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · August 06, 2024

Outcomes of Trastuzumab–Deruxtecan Therapy in Patients With HER2+ Breast Cancer and Active Brain Metastases

Neuro-Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Neuro-Oncology
FINAL outcome ANALYSIS FROM THE PHASE II TUXEDO-1 TRIAL OF TRASTUZUMAB-DERUXTECAN IN HER2-positive breast cancer PATIENTS WITH active brain metastases
Neuro-oncology 2024 Jul 04;[EPub Ahead of Print], R Bartsch, AS Berghoff, J Furtner, M Marhold, ES Bergen, S Roider-Schur, MJ Mair, AM Starzer, H Forstner, B Rottenmanner, MB Aretin, K Dieckmann, Z Bago-Horvath, H Haslacher, G Widhalm, A Ilhan-Mutlu, C Minichsdorfer, T Fuereder, T Szekeres, L Oehler, B Gruenberger, G Pfeiler, C Singer, A Weltermann, L Berchtold, M Preusser

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Brain Cancer Center of Excellence

Visit our Brain Cancer Center of Excellence for additional, in-depth coverage.


Further Reading